Iovance Biotherapeutics to Host Virtual Roundtable with Key Opinion Leaders to Discuss Melanoma Treatment Landscape
20 Junho 2023 - 8:01AM
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology
company focused on innovating, developing, and delivering novel
polyclonal tumor infiltrating lymphocyte (TIL) therapies for
patients with cancer, will host an investor conference call and
webcast to discuss lifileucel TIL therapy and the emerging melanoma
treatment landscape on June 26, 2023, at 5:00 p.m. ET.
During the one-hour event, the Iovance leadership
team will provide a brief recap of the C-144-01 trial and clinical
data, defined regulatory pathway, and pre-commercial activities for
lifileucel in advanced post-anti-PD-1 melanoma. A multidisciplinary
panel of key opinion leaders (KOLs) will discuss the disease burden
and unmet needs for advanced melanoma patients within current
treatment practices, perspectives on TIL therapy and the emerging
landscape, and preparations for broad adoption of lifileucel and
cell therapies within their treatment centers.
The KOL roundtable will be moderated by Dr. Brian
Gastman, Executive Vice President, Medical Affairs at Iovance and a
practicing surgeon who consults and operates on cancer patients at
the Cleveland Clinic. Prior to his recent arrival at Iovance, Dr.
Gastman led the melanoma clinical trials team, including as lead
investigator on numerous trials of TIL and other cell therapies, as
Co-Medical and Surgical Director of Cleveland Clinic and Taussig
Cancer Center’s melanoma and high-risk skin cancer program.
To participate in the webcast Q&A, please
register at
https://register.vevent.com/register/BI5f5b5df5576e42d2bf3535abcc93c3df,
or to view only register at
https://edge.media-server.com/mmc/p/n4tkb4ft. The live and archived
webcast can be accessed in the Investors section of the Company’s
website, IR.Iovance.com. The archived webcast will also be
available for one year.
Virtual KOL Event AgendaIntroduction: Recap
of Lifileucel TIL Therapy Development & Regulatory
Pathway
Multidisciplinary KOL
Roundtable:Perspectives on Lifileucel and Advanced
Melanoma Treatment Landscape
|
|
|
|
|
|
|
Participant |
Title |
|
TIL Experience |
|
|
Brian Gastman, M.D. (moderator) |
EVP, Medical Affairs at Iovance Biotherapeutics and practicing
surgeon at the Cleveland Clinic |
|
Lead investigator of TIL trials at Cleveland Clinic |
|
|
|
|
|
|
|
|
Krishna Komanduri, M.D. |
Professor and Chief, Division of Hematology and Oncology, Dept. of
Medicine; Physician-in-Chief, Helen Diller Family Comprehensive
Cancer Center; Clinical Director, Living Therapeutics Initiative,
University of California San Francisco (UCSF) |
|
Chair of TIL Working Group (TIL-WG), dedicated to educating
healthcare practitioners about TIL therapyPast President, American
Society for Transplantation and Cellular Therapy (ASTCT) |
|
|
|
|
|
|
|
|
Mario Sznol, M.D. |
Medical oncologist at Yale Medicine; co-director of the Cancer
Immunology Program at Yale Cancer Center |
|
Iovance Scientific Advisory Board member |
|
|
|
|
|
|
|
Live Audience Q&A Session
About Iovance Biotherapeutics,
Inc.Iovance Biotherapeutics aims to be the global leader
in innovating, developing and delivering tumor infiltrating
lymphocyte (TIL) cell therapies for patients with cancer. We are
pioneering a transformational approach to cure cancer by harnessing
the human immune system’s ability to recognize and destroy diverse
cancer cells in each patient. Our lead late-stage TIL product
candidate, lifileucel for metastatic melanoma, has the potential to
become the first approved one-time cell therapy for a solid tumor
cancer. The Iovance TIL platform has demonstrated promising
clinical data across multiple solid tumors. We are committed to
continuous innovation in cell therapy, including gene-edited cell
therapy, which may extend and improve life for patients with
cancer. For more information, please visit www.iovance.com.
Forward-Looking StatementsCertain
matters discussed in this press release are “forward-looking
statements” of Iovance Biotherapeutics, Inc. (hereinafter referred
to as the “Company,” “we,” “us,” or “our”) within the meaning of
the Private Securities Litigation Reform Act of 1995 (the “PSLRA”).
All such written or oral statements made in this press release,
other than statements of historical fact, are forward-looking
statements and are intended to be covered by the safe harbor for
forward-looking statements provided by the PSLRA. Without limiting
the foregoing, we may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,”
“may,” “could,” “might,” “will,” “should” or other words that
convey uncertainty of future events or outcomes and are intended to
identify forward-looking statements. Forward-looking statements are
based on assumptions and assessments made in light of management’s
experience and perception of historical trends, current conditions,
expected future developments and other factors believed to be
appropriate. Forward-looking statements in this press release are
made as of the date of this press release, and we undertake no duty
to update or revise any such statements, whether as a result of new
information, future events or otherwise. Forward-looking statements
are not guarantees of future performance and are subject to risks,
uncertainties and other factors, many of which are outside of our
control, that may cause actual results, levels of activity,
performance, achievements and developments to be materially
different from those expressed in or implied by these
forward-looking statements. Important factors that could cause
actual results, developments and business decisions to differ
materially from forward-looking statements are described in the
sections titled "Risk Factors" in our filings with the Securities
and Exchange Commission, including our most recent Annual Report on
Form 10-K and Quarterly Reports on Form 10-Q, and include, but are
not limited to, the following substantial known and unknown risks
and uncertainties inherent in our business: the effects of the
COVID-19 pandemic; risks related to the timing of and our ability
to successfully develop, submit, obtain and maintain U.S. Food and
Drug Administration (“FDA”) or other regulatory authority approval
of, or other action with respect to, our product candidates, and
our ability to successfully commercialize any product candidates
for which we obtain FDA approval; whether clinical trial results
from our pivotal studies and cohorts, and meetings with the FDA,
may support registrational studies and subsequent approvals by the
FDA; preliminary and interim clinical results, which may include
efficacy and safety results, from ongoing clinical trials or
cohorts may not be reflected in the final analyses of our ongoing
clinical trials or subgroups within these trials or in other prior
trials or cohorts; the risk that enrollment may need to be adjusted
for our trials and cohorts within those trials based on FDA and
other regulatory agency input; the changing landscape of care for
cervical cancer patients may impact our clinical trials in this
indication; the risk that we may be required to conduct additional
clinical trials or modify ongoing or future clinical trials based
on feedback from the FDA or other regulatory authorities; the risk
that our interpretation of the results of our clinical trials or
communications with the FDA may differ from the interpretation of
such results or communications by the FDA (including from the prior
pre-BLA meeting with the FDA); the risk that the FDA may not
approve our BLA submission for lifileucel in metastatic
melanoma; the acceptance by the market of our product candidates
and their potential reimbursement by payors, if approved; our
ability or inability to manufacture our therapies using third party
manufacturers or our own facility may adversely affect our
potential commercial launch; the results of clinical trials with
collaborators using different manufacturing processes may not be
reflected in our sponsored trials; the risk that unanticipated
expenses may decrease our estimated cash balances and forecasts and
increase our estimated capital requirements; and other factors,
including general economic conditions and regulatory developments,
not within our control.
CONTACTS
Iovance Biotherapeutics, Inc:Sara
Pellegrino, IRCSenior Vice President, Investor Relations &
Corporate Communications650-260-7120 ext.
264Sara.Pellegrino@iovance.com
Jen SaundersDirector, Investor Relations &
Public Relations267-485-3119Jen.Saunders@iovance.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024